Genmab A/S (NASDAQ:GMAB) Receives $49.50 Consensus Price Target from Analysts

Genmab A/S (NASDAQ:GMAB) has been given an average recommendation of “Hold” by the thirteen ratings firms that are currently covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $49.50.

A number of research analysts have recently issued reports on GMAB shares. Morgan Stanley reaffirmed an “underweight” rating on shares of Genmab A/S in a research report on Tuesday, March 26th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research report on Thursday. Truist Financial increased their price objective on Genmab A/S from $50.00 to $53.00 and gave the company a “buy” rating in a report on Tuesday, June 4th. Finally, BTIG Research upped their target price on Genmab A/S from $46.00 to $47.00 and gave the company a “buy” rating in a research report on Thursday.

Genmab A/S Stock Down 1.8 %

Shares of NASDAQ:GMAB opened at $25.13 on Friday. The company has a market capitalization of $16.62 billion, a price-to-earnings ratio of 20.94, a price-to-earnings-growth ratio of 0.91 and a beta of 0.99. The firm has a 50 day moving average of $27.96 and a 200 day moving average of $29.09. Genmab A/S has a 52 week low of $24.94 and a 52 week high of $42.72.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Thursday, May 2nd. The company reported $0.16 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.16. The firm had revenue of $603.30 million during the quarter, compared to analysts’ expectations of $594.23 million. Genmab A/S had a return on equity of 18.90% and a net margin of 30.74%. On average, sell-side analysts expect that Genmab A/S will post 1.11 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. HighTower Advisors LLC grew its position in Genmab A/S by 30.7% during the third quarter. HighTower Advisors LLC now owns 9,009 shares of the company’s stock valued at $322,000 after buying an additional 2,114 shares during the period. Citigroup Inc. increased its stake in shares of Genmab A/S by 148.2% in the 3rd quarter. Citigroup Inc. now owns 21,545 shares of the company’s stock valued at $760,000 after purchasing an additional 12,863 shares in the last quarter. FMR LLC raised its holdings in Genmab A/S by 6.3% in the 3rd quarter. FMR LLC now owns 422,437 shares of the company’s stock worth $14,899,000 after purchasing an additional 24,936 shares during the period. Mariner LLC boosted its position in Genmab A/S by 183.4% during the third quarter. Mariner LLC now owns 49,018 shares of the company’s stock worth $1,729,000 after purchasing an additional 31,720 shares in the last quarter. Finally, Northern Trust Corp grew its holdings in Genmab A/S by 83.3% in the third quarter. Northern Trust Corp now owns 559,044 shares of the company’s stock valued at $19,717,000 after purchasing an additional 254,042 shares during the period. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.